Keyphrases
Metastatic Renal Cell Carcinoma (mRCC)
100%
Treatment Decisions
100%
Cytoreductive Nephrectomy
100%
Evolving Roles
100%
Improved Outcomes
40%
Genetic Modification
40%
Vascular Endothelial Growth Factor
40%
Primary Tumor
40%
Targeted Therapy
40%
Tumor Heterogeneity
40%
High-level Expression
20%
Effector Genes
20%
Predictive Role
20%
Mammalian Target of Rapamycin (mTOR)
20%
Somatic mutation
20%
Gene Signature
20%
Rapid Progression
20%
Patient Selection
20%
Angiogenic
20%
Multiple Sites
20%
MTOR Inhibitor
20%
Systemic Treatment
20%
Metastatic Tumor
20%
Somatic Copy number Alterations
20%
TSC1
20%
Response to Immunotherapy
20%
Clinical Applicability
20%
Growth Factor Pathway
20%
Gene Single nucleotide Polymorphism
20%
Treatment Timing
20%
PTEN Expression
20%
Genetic Outcome
20%
Chromatin Remodeling Genes
20%
TSC2 mutation
20%
PBRM1
20%
Pathway mutation
20%
PBRM1 mutation
20%
Medicine and Dentistry
Kidney Metastasis
100%
Nephrectomy
100%
Gene Mutation
40%
Primary Tumor
40%
Vasculotropin
40%
Targeted Therapy
40%
Somatic Mutation
20%
Somatics
20%
Single Nucleotide Polymorphism
20%
Metastatic Carcinoma
20%
Immunotherapy
20%
Systemic Therapy
20%
Chromatin Remodeling
20%
Mechanistic Target of Rapamycin
20%
Patient Selection
20%
Mammalian Target of Rapamycin Inhibitor
20%